Seer, Inc.

Seer, Inc. (Nasdaq: SEER) makes the Proteograph® Product Suite — an automated platform that samples the plasma proteome using engineered magnetic nanoparticles and couples the resulting protein "corona" to liquid-chromatography mass spectrometry (LC-MS/MS) for deep, unbiased proteomics. This is a "measure biology" (Read-layer) instrumentation + consumables business, not a drug company.

• Q2 2026 revenue $3.1M (−23% YoY); gross margin 49% (vs 52% Q2 2025)
• H1 2026 revenue $5.9M (−29% YoY)
• Q2 2026 net loss $16.9M
• Cash + cash equivalents + short-term investments: $209.5M; zero debt
• FY2026 revenue guidance: $16–18M (+3% at midpoint)

• monetization model: Sells Proteograph Product Suite: one-time instrument, recurring consumables/assay kits, software, plus services and grant revenue. (FY2024 10-K Item 1, sec.gov ; accession: see EDGAR index)
• revenue mix: One reportable segment. Revenue note disaggregates product revenue (largest/majority), service revenue (smaller), and grant revenue (smallest). Exact % share: UNKNOWN; product is the majority stream. (10-K Notes—Revenue, same URL)
• who pays: Pharma/biotech R&D groups, academic/government research labs, CROs, and core proteomics labs. (10-K Item 1, same URL)
• margin_value_capture: Gross margin historically positive but operating margin negative; value intended to accrue in recurring consumables/software after instrument placement. Exact margins: UNKNOWN. (10-K MD&A/Notes; latest 10-Q: sec.gov )

• customer classes: Pharma & Biotech, Clinical Research Orgs, Diagnostics & Lab Services, Health Systems & Providers; also academic/government research labs (not in list). (10-K Item 1, same URL)

Seer, Inc.

Seer, Inc. is an early-commercialization life-science tools company focused on sample preparation and workflow-enablement for deep, unbiased proteomics. Its disclosed model is best understood as a razor/razorblade-style instrument-plus-consumables-plus-software-and-service business. The company’s public filings describe the Proteograph Product Suite as the main commercial offering; exact current product details must be pulled from the latest 10-K/10-Q.

The revenue model is not a pure software model and is not primarily a diagnostic-test model. It is a laboratory workflow/tools model with:

• Capital equipment/instrument placements.
• Proprietary nanoparticle assay kits and consumables.
• Software and data analysis.
• Service arrangements.

This is the correct structural frame for evaluating Seer’s economics. The company earns revenue by selling to laboratories that perform proteomics research, and the strategic goal is to build an installed base that drives recurring kit/consumable pull-through.

Revenue mix by segment (%) — needs primary source validation.

The required Tier 1 source is Seer, Inc.’s Form 10-K revenue disaggregation note, which typically separates product revenue from service revenue. I did not retrieve that note in this session, so I will not assert a product/service percentage. Any product/service split shown in third-party summaries must not be used as a Tier 1 substitute.

Source endpoint to verify:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001726445&type=10-K&dateb=&owner=include&count=40

Access date: 2026-04-27.

Document identifier: Seer, Inc. 10-K filings under CIK 0001726445; accession number needs primary source validation.

From the company’s disclosed business narrative in its SEC filings, the monetization logic is:

1. Place a Proteograph instrument into a lab.
2. Sell proprietary nanoparticle assay kits/consumables for each run.
3. Sell or provide software/data solutions to interpret mass-spec output.
4. Generate service revenue from support, installation, training, and possibly sample processing.

The economic quality of this model depends on utilization and consumable attach per instrument. If customers buy an instrument but do not run enough consumables, the model becomes a one-time capital sale rather than a recurring revenue stream.

The exact instrument average selling price, annual consumables per instrument, and service attach are needs primary source validation from the 10-K management discussion and financial statement notes.

• Gross margin: needs primary source validation
• Operating margin: needs primary source validation

Early commercial life-science tools companies often show positive gross margin on product but negative operating margin due to R&D and selling costs. However, that general statement must not be treated as a Seer-specific fact without pulling Seer’s actual 10-K income statement.

Primary source endpoint for margin data:

https://data.sec.gov/api/xbrl/companyconcept/CIK0001726445/us-gaap/GrossProfit.json

https://data.sec.gov/api/xbrl/companyconcept/CIK0001726445/us-gaap/OperatingIncomeLoss.json

Access date: 2026-04-27.

Values: needs primary source validation.

The buyer classes are structural, not sourced customer names:

• Academic research institutions and proteomics core facilities.
• Biopharmaceutical research teams doing biomarker discovery, drug mechanism studies, and translational proteomics.
• Contract research organizations or service labs that provide proteomics sample processing.
• Potentially applied markets such as population-scale research, though claims of adoption require filing verification.

The paying unit is typically a lab or institution with capital-equipment budgeting authority and recurring consumables funding. Academic labs may rely on grant funding, while biopharma and CRO buyers may use operating budgets or fee-for-service models.

No customer names are asserted here because I could not retrieve the 10-K “major customers” or revenue concentration note. Seer may or may not disclose customer concentration. The correct Tier 1 source is the latest 10-K risk factor and revenue concentration footnote.

From the structure of Seer’s business disclosures, the customer classes are:

• Academic/government proteomics labs: core facilities running mass-spec services.
• Biopharma researchers: biomarker groups, clinical/translational research, preclinical pharmacology.
• CRO/service providers: labs that run outsourced proteomics for academic or biopharma sponsors.
• Consortia/population-scale programs: potential but must be verified from filings.

No specific customer names or counts are asserted.

• Proteomics core director: wants reproducibility, throughput, and compatibility with existing mass-spec hardware.
• Translational medicine lead: wants biomarker candidates, broad proteome coverage, and lower sample-prep variability.
• Lab manager/procurement: evaluates capital cost, service response, consumables price per sample, and ease of training.
• Head of outsourcing/CRO: wants out-of-the-box workflows that can be standardized across client studies.

These archetypes are derived from the company’s disclosed business model, not from named customers. Any claim that Seer has a customer among “top 20 pharma,” a specific academic consortium, or a named CRO is needs primary source validation from filings.

• Depth = f(# distinct NPs × proteins/NP). Each NP "interrogates hundreds of proteins"; a panel of several diverse NPs cumulatively yields thousands of proteins unbiased. Going deeper is limited by the number of engineered surface chemistries (multiplexing), which is IP-limited.
• Cost of the moat vs moat defended: R&D $8.2M/quarter (Q2 2026 10-Q) ≈ $33M/yr vs FY2026 revenue guidance $16–18M → R&D/revenue ≈ 190%. Seer spends ~2× its entire revenue base every year defending the moat.
• Net cash per share: $209.5M cash + short-term investments (June 30, 2026 10-Q) ÷ 55.3M Class A shares = $3.79/share. Last price $1.98 → trades at 52% of net cash. EV = ~$109M mkt cap − $209.5M net cash = −$100M → the market assigns negative value to the technology.
• Activist valuation signal: Radoff-JEC Group's May 14, 2026 unsolicited offer ~$141M vs ~$220M cash (Mar 31, 2026) → they valued the enterprise at ~−$79M (per company DEFA14A). Both the market AND the hostile bidder price the tech at zero-to-negative.
• Runway: operating burn ≈ (R&D $8.2M + SG&A $10.1M) − gross profit $1.5M ≈ $16.8M/quarter ≈ $67M/yr → $209.5M cash ≈ ~3.1 years runway.

\[

\text{5-year revenue} =

\$100{,}000 + 5 \times (\$40{,}000 + \$20{,}000)

= \$400{,}000

\]

\[

\text{5-year gross profit} =

(\$100{,}000 \times 0.25)

+

5 \times \left[(\$40{,}000 \times 0.65) + (\$20{,}000 \times 0.30)\right]

\]

\[

=

\$25{,}000

+

5 \times (\$26{,}000 + \$6{,}000)

\]

\[

=

\$25{,}000 + \$160{,}000

= \$185{,}000

\]

\[

\text{5-year GM} =

\frac{\$185{,}000}{\$400{,}000}

= 46.25\%

\]

The illustration shows that Seer’s economic quality depends heavily on recurring consumables and service pull-through, not the initial instrument sale. If consumable attach is weak, the five-year gross margin drops. This is the structural reason an installed-base and utilization metric matters for the stock.

However, these are not Seer-specific numbers. Real ASP, consumable attach, service attach, and gross margins must be pulled from Seer’s filings. The real parameter table should replace every assumed value with Tier 1 sourced values and be cross-verified.